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ABSTRACT
Preimplantation Genetic Diagnosis (PGD) is a reproductive medicine technology that
allows the genetic characteristics of embryos to be examined. Created through in vitro
fertilization, embryos are grown in a Petri dish for three days, at which point they have
eight cells. One cell is then removed from each embryo and tested for certain genetic
characteristics. Based on the results, selected embryos are transferred into a woman's
uterus.
Originally developed as a way to screen embryos for genetic disorders, PGD was used
among a limited number of patients. More recently, however, some physicians and
researchers have deemed PGD a useful infertility treatment. As a result, the number of
people using PGD has increased every year since the technology was first developed in
1989.
The role of PCGD as an emerging infertility treatment was examined from research,
clinical, and personal perspectives. This was done through literature searches, interviews,
laboratory observations, and attendance at infertility support meetings.
Thesis Advisor: Marcia Bartusiak
Title: Visiting Professor of Writing and Humanistic Studies
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At 7:05 a.m. the phone rings, and Kevin DeLegge lets out a sigh.
"That's someone calling to apologize for running late," he says.
The embryologists at the Fertility Centers of New England must get to work early.
Before a day of embryo transfers and egg retrievals begins, a delicate test called PGD has
to be started.
At the center, Patient 98523 had recently been taking drugs at the clinic to
stimulate her ovaries into producing extra eggs. Then later, three days ago, this patient
and her husband came back into the clinic, where she was anesthetized and her eggs
siphoned out; he spent some time down the hall in a tiny room full of magazines not sold
to children under the age of eighteen. Today, Kevin will carefully manipulate the nine
embryos that resulted in the union of his sperm and her egg.
In the infertility world, time is not measured in days, months, or years, but cycles:
that twenty-eight day window of opportunity between ovulations, when a woman will
either become pregnant or won't. Patient 98523's chart clearly documents seven
unsuccessful cycles.
Doctors tried to get her pregnant four times by intrauterine insemination (IUI).
Four times, a long thin tube was snaked up her vagina and into her uterus, delivering
sperm more directly to her egg. Next they tried three cycles of in vitro fertilization (IVF).
Three times, her eggs were sucked from her ovaries, fertilized in the lab, and then the
artificially conceived embryos were inserted back into her uterus. Again, she failed to
become pregnant. Her chart notes that all seven assisted reproductive cycles were
negative-negative for pregnancy. This time, following her doctor's recommendation,:_' "b-''~' b"'J "' ""'""''
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they are trying the newest acronym in the medical staff's artillery: PGD or
preimplantation genetic diagnosis.
PGD is essentially one extra step in the in vitro fertilization procedure. Embryos
are still created in a Petri dish from a couple's sperm and egg and then transferred back to
the woman's uterus. But with PGD, before the embryos are transferred, each tiny eight-
cell embryo is tested for genetic diseases and abnormalities. Based on the results, only the
best-fit embryo is selected. It's presumed that infertility patients will be more likely to get
pregnant if the best embryo is chosen.
This wasn't the original purpose of PGD. The test was initially designed to help
couples at high risk for specific inheritable diseases. By testing the embryos and then
selecting the ones that don't carry the family's genetic mutation the tragedy of conceiving
what would become a sick child is avoided. In 1989, the first successful PGD was
performed to select a female embryo for a couple, because a boy would have had a 50
percent chance of inheriting a severe disease. Then in 1992, the first PGD baby to be
screened for a single gene mutation, cystic fibrosis, rather than for a sex linked disease
was born. PGD is also used for selecting a genetic match. Parents, who have a sick child
in need of a stem cell transplant, can try to have another child who may be a compatible
donor. For many children with leukemia, for example, their only hope is a bone marrow
transplant from a genetic match. Without PGD, there is a one in four chance that the
blood from a new sibling's umbilical cord, which contains stem cells, will be a match for
the sick child. But with PGD, these parents can now select the embryo that will grow into
the infant that has the specific genetic characteristics that can save the sibling's life.
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But over the last decade, the use of PGD has changed dramatically. Currently, the
vast majority of people doing PGD come from infertility clinics and, unlike avoiding a
genetic disease or selecting a stem-cell match, the benefits, if any, are less obvious. For
parents who are both carriers for cystic fibrosis, a successful cycle of PGD helps them
have a child without the disease. For a couple struggling with infertility, the goal is to get
pregnant. Whether PGD is actually helping is still in question. Some doctors involved
with the development of PGD believe that it won't help most infertility patients at all. Yet
others, who have been in the game almost as long, believe that PGD should be done on
every IVF cycle.
There is money to be made and lost by clinics and the health industry. And for
couples, there is hope to build up and tear down. Springing from every issue surrounding
this technique is the question, is PGD worth it? Should this new technology be applied to
one and all? At what cost to couples seeking infertility treatment? At what cost to
society? The only certain thing about this emerging technology is that disagreement lies
at every turn.
The logic for providing infertility patients with PGD testing is based on a few
known facts. First, as a woman ages, she produces a higher percentage of abnormal eggs.
When she is over 35 years old, 50% of her eggs will be abnormal, and when she is over
40 year old 80%o will be abnormal. Embryos generated from abnormal eggs will typically
fail, resulting in either miscarriage or no pregnancy at all. When a woman undergoes
IVF, she creates more embryos than can be transferred back into her. This leaves room
for the selection of the best embryo. If embryos made from normal eggs are selected over
the abnormal ones than the chance of a woman getting pregnant increases.
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Unlike IVF though, which resulted in more than 45,000 births in 2002 alone and
accounts for slightly more than I % of annual US births, PGD has helped make only
around 1,000 babies since it was first successfully used in 1989. This is due to its relative
newness and limited use. Yet each year the number of patients trying PGD has doubled,
and most medical professionals expect this trend to continue. And the number of
physicians that recommend it climbs. Like it or not, few deny that PGD represents the
future of reproductive medicine.
Before the embryos are taken out of the incubator, Kevin prepares for the test.
Better to take the time now than later. Besides, embryos can't be moved from one dish
into another until someone else arrives.
"We have a witnessing program. If I want to move an embryo out of a drop into
another dish, I want someone here to make sure that I have the right dishes. Just take a
peek at the names, make sure they match. It protects everybody," Kevin says.
As a woman ages, what gets scrambled in her eggs are the chromosomes. Wound
up into 46 separate structures within a cell's nucleus, the chromosomes contain all the
instructions for the life of an embryo, an infant, and an adult. When an egg and a sperm
meet, each parent is delivering half of their own genetic material to the embryo. When 23
chromosomes from mom and 23 from dad merge, a genetically unique single cell is
created that can then grow into a normal embryo. What is lost with age is a woman's
ability to produce eggs with the correct number of chromosomes. Some eggs get 22 or
24, others get all 46 or none at all. If these eggs are fertilized they will usually become an
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embryo that will not implant into the uterus or if they do, will often result in a
miscarriage.
That's what's been happening to patient 98523. She's 35 years old, and the phrase
"advanced maternal age" is noted on in her chart. Her increased risk for producing
abnormal eggs might be the reason why she isn't getting pregnant. Her doctor explained
that if they could select the normal embryos by using PGD she might finally carry to
term. This test, now in the hands of Kevin, will cost her an additional $2,500.
Thomas O'Leary, another embryologist strolls into the lab. "How do they look?"
he asks about the embryos.
"I don't know," says Kevin. "I haven't seen them yet. It's going to be a surprise."
Tom checks the names quickly, and Kevin moves the embryos from the Petri
dishes where embryos are grown, into the bench-top dish.
PGD has several steps. It's Kevin's job to tackle the first and most crucial
procedure: the cell biopsy. He will carefully take one cell out of each of patient 98523's
nine embryos. To do that he must first break through the membrane that surrounds the
embryo to gain access to the individual cells. Then he carefully sucks out one cell without
disturbing the rest of the embryo.
He works with three embryos at a time and grades each based on the number of
cells it has and the quality of the embryo's morphology. In the best-case scenario, a three-
day-old embryo will have eight cells, but many don't. The quality of the embryo is scaled
from one to five: one being the "prettiest" embryo and five being the "ugliest." The traits
that determine its loveliness are the graininess of the nuclei, the relative size of the cells,
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the presence of cell fragments, and the shape and thickness of the membrane that
surrounds the embryo.
In the first group of three, one embryo is of very poor quality with only five cells,
the next is a fairly nice eight-celled embryo, and the last has only three cells. Kevin won't
even bother to biopsy that one because it is in such poor shape.
He carefully adjusts his weight in the chair and focuses the microscope on the
five-celled embryo.
"You gotta get in a zone for PGD," he smiles before slipping a red tipped tube
into his mouth.
Very delicately, he moves the needle over to the embryo and blows out a small
amount of acid. This creates a hole in the zona, which is a membrane that temporarily
surrounds an embryo in its early stages and holds the cells close together. Kevin is doing
artificially what would happen naturally in the uterus: a stage that is called hatching.
After hatching the embryo, he changes needles and places a green tipped tube
carefully between his lips. Very slowly, he breathes in, pulling one cell away from the
embryo. When the cell is finally extracted, he quickly moves it to the other side of the
dish. His shoulders relax and the mouthpiece falls away from his lips. He gives the lone
cell a good looking over to make sure that the nucleus can be seen.
The next embryo to be biopsied is the nicest. It's an eight cell, and Kevin gives it
a quality score of two. If the lab were not doing PGD, today, this would be the embryo
transferred back into Patient 98523's uterus on looks alone. So if the results come back
saying that this embryo is genetically normal, then there was no point in doing PGD.
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By 8:15 a.m., after an hour of work, Kevin finishes biopsing the last set of three
embryos. With a sigh of relief he hands the three single cells off to Alison Finn for the
next step in the procedure: the fixation.
In order to examine a cell's chromosomes, its nucleus must be firmly fixed onto a
microscope slide. This is done by swelling the cell until it bursts onto the glass, leaving
the nucleus stuck. First developed in the 1960s, fixation is a common procedure in
thousands of laboratories. But most of the samples worked on are blood or amniotic fluid,
which contain hundreds or thousands of cells. When Alison fixes the biopsied cells, she
has only a single chance with each one. She will line up the nuclei on a glass slide,
marking each microscopic spec with a diamond point pen, and ship them off for analysis.
"It's very simple, it's just nerve wracking," she says.
To begin, Alison adds the solution, swelling the first cell in the line up. Standing
at the microscope, ready to pounce, she adds the fix at just the right moment.
"Shit. There it is. That one jumped, but I was able to find it," she says.
If you drop a little too much fix on the bloated and bursting cell, it can fly right
off the slide or into one of the other cells. When this happens, the embryo must have a
second cell removed. Embryos that have two cells sucked out are half as likely to lead to
pregnancy as those that are only biopsied once. When PGD is used to prevent a disease,
the need for accurate genetic information outweighs the additional harm to the embryo
from a second biopsy. But for infertile couples, the goal is to get pregnant, not examine
chromosomes. The decreased rate of pregnancy caused by a second biopsy can make
PGD for infertility pointless.
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Because laboratories only have one cell to test, PGD for chromosomes has a 10
percent misdiagnosis rate. PGD is crude compared to genetic testing done on blood
samples, which are always well over 99 percent accurate. This is because thousands of
cells are examined with blood samples, where as PGD tests only one. Embryologists who
opt for two-cell biopsy may achieve a more accurate genetic picture of the embryos, but
the chance of the patient getting pregnant is slashed in half. Out of fear of misdiagnosis,
many European laboratories routinely take two cells from each embryo. While this
caution may be necessary for couples trying to avoid a genetic disease, infertility patients
do not benefit. For PGD to be useful, the laboratory must get it right the first time. And as
Alison performs the fixation, this thought is never far from her mind.
The LCD screen on the humidifier reads 40%-exactly where it should be. The
moist air keeps the solution that bloats the cell from evaporating. Alison breathes heavy
onto the microscope slide. After adding the fix she explains, "Huffing, even though you
look like an idiot, adds humidity to the slide so that it doesn't dry up."
The last cell fixes easily and Alison exclaims, "Ah, here it is, and it's so pretty."
The nucleus isn't grainy, it's spread wide, and it's the proper distance from the other
nuclei on the slide. The slides are then packed in a large box and driven by a courier
service to their next destination. They will arrive half-a-day later in West Orange, New
Jersey, at the Reprogenetics laboratory. After each cell's chromosomes are tagged with
florescent markers and carefully examined for abnormalities. The results are phoned back
to FCNE. This highly coordinated effort ends less than 36 hours from the time Kevin first
took Patient 98523's embryos out of the incubator.
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Dr. Lynette Scott is in charge of the advanced reproductive technology laboratory
at FCNE. She has been a laboratory director for more than 16 years and before that
worked in reproductive medicine research for five. No stranger to the intrinsic drama of
the field, when asked what she does for a living she casually replies, "I make babies."
"Someone's hopes and dreams are relying on the embryos that you're biopsing
and fixing," says Scott. "You're working with one nucleus. And one nucleus comes from
one embryo that can potentially make one baby. It's intense."
She has a small office, but that doesn't stop her from turning it into the unofficial
embryologist break room. After the first embryo transfer and egg retrieval of the morning
Kevin, Allison, and Tom buzz in and out to grab gulps of coffee. Proud of her team, she
is more than happy to reward them with half of her office and lots of caffeine.
"You need a highly skilled, dedicated person to do the biopsy and the fixation,"
says Scott. "Not any old ninny can go and do it."
The need for competent technicians is often the limiting factor in how many PGD
procedures a clinic can perform per year. In the past, FCNE conducted only 50 PGDs per
year, its maximum capacity. Starting in 2004, however, Scott reorganized and cross-
trained her staff so that every patient who wanted to do PGD could get it. By the end of
that year, 180 PGDs had been performed. Scott wants this number to climb even higher.
"I came into this whole process sitting on the fence," she says. "I almost want to
do PGD on everybody now."
As a scientist, Scott wants to gather as much information as possible about a
patient and her embryos. She examines the clinical history, the eggs and sperm, and the
embryos' morphology, all in search for the cause of a couple's infertility. PGD provides
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her with a new lens for examining a case-a look at each embryo's chromosomes. Scott
embraces PGD not as a treatment, but as a way to identify and better understand the
causes of infertility.
For example, take the case of a 34-year-old woman who has gone through three
cycles of IVF and is still not pregnant. In each cycle she produces very pretty embryos,
and the doctors can't figure out what's going wrong. PGD is added on her fourth try, and
the laboratory reports that only five percent of her embryos are normal. Her inability to
become pregnant is explained, even if the reason why she has so few normal embryos is
not.
The exact opposite results are also useful. Another 34-year-old, for whom IVF has
also repeatedly failed, does PGD and learns that 70 percent of her embryos are normal.
The doctors now know that for this patient, the chromosomes are not the problem. Maybe
it's the endometrium, the lining of her uterus. Maybe the hormonal support from the
ovary is off. Maybe it's some other physiological cause. PGD has ruled out one potential
obstruction, but the cause of her infertility is still unknown.
As a tool for gaining insight into a patient's infertility problems, PGD works. And
in Scott's opinion, that makes it a very valuable technique. But when a patient agrees to
pay the additional $2,500 out of pocket for PGD, her goal is to get pregnant. PGD is
caught in a twilight zone: it's a treatment but also a valuable research tool. The difference
can get lost. The test is pitched to patients as a technique that will increase the chance of
pregnancy, because only normal embryos will be transferred. That PGD is sometimes
called a "treatment" and other times a "test" leaves some professionals uneasy.
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When doctors offer patients a new technology that will report their embryos'
chromosomal status and may provide answers to their infertility, few people decline the
test. These couples are desperate to have a baby and will gladly find hope in the latest
technique. But there is a big difference between getting answers and getting a baby.
"There are definitely some cases where PGD will never, ever, give them a baby,
but it may give them closure," says Alison. "And if they are financially secure and they
want to do that, that's fine. Because these people will always ask, what if? What if I
drank more orange juice?"
PGD results that explicitly show that a woman is not making normal embryos can
help a couple move on to either adoption or a donor egg procedure. The case of Patient
98523 will likely end this way. Her doctors probably recommended PGD because they
didn't know what else to do.
It's not the scientists that are leaving patients confused about the true benefits of
PGD; people who hold PhDs, like Scott, rarely come in contact with patients. They do
not hand out pamphlets claiming, "PGD offers new hope for enhancing the probability of
a healthy baby." Confusion arises in the way that PGD is marketed.
Doctors establish their fertility clinics by advertising that they can get people
pregnant. This leads to competition between clinics that is both real and often fierce. In
the United States, more than a billion dollars was spent on IVF treatments in 2002 alone.
But PGD is a technology that not every fertility center can perform, and so for a clinic
that does offer the testing this can be a selling point-a way to increase the bottom line.
While the doctors promote their clinic and advertise PGD as the next big thing,
the folks back in the lab are more ambivalent. PGD can certainly help some couples gets
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pregnant and provide others with answers or closure. But scientists, like Scott, add a note
of reservation to their enthusiasm. She firmly states that checking chromosomes is only
one piece in the much bigger puzzle of infertility. PGD is a tool, not a cure. But that's not
what doctors who own and operate the clinics want to hear. So they call PGD a "new
hope," while the scientists call it a "new test."
"In this field everybody's looking for the golden bullet. I've seen the golden
bullet a number of times," she says.
New culture medias, assisted hatching, ICSI (Intracytoplasmic Sperm Injection),
and "embryo glue" were all labeled golden bullets when they were first developed. Some
of these advances led to higher success rates, but others fell by the wayside. Self-
promotion and the search for the next big thing are ever-present features in this field.
Knowing this history, Scott never joined the camp that claimed PGD would solve
everyone's fertility problems. In 1993, when doctors first stood up at conferences
proclaiming the good news of PGD, she was skeptical.
Eventually PGD's biology, rather than its clinical success rates, convinced her it
was worth it. Before PGD was developed, the only way to assess an embryo was to watch
it grow. What does the egg look like? What does the sperm look like? How is the embryo
maturing? Today, Scott can use PGD to look deeper into an embryo's biology and ask,
what do the chromosomes look like? Even if it isn't a golden bullet, at least it's a step
toward understanding the root causes of infertility.
But the fertility industry doesn't step slowly and carefully in pursuit of success.
Instead, it runs frantically in all directions, trying to stay ahead in a race where no one
knows the location of the start and finish. Doctors advertise the latest technological
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developments before the scientific community has empirical data supporting any true
benefit.
Take the case of EmbryoGlue, a culture medium that includes special nutrients
absorbed by embryos. These nutrients supposedly help an embryo attach more firmly to
the uterus once they have been transferred. Doctors everywhere began using it as soon as
it hit the shelves. Websites of fertility clinics started advertising that they used
EmbryoGlue, calling it a superior medium that increased chances of pregnancy. After
studies confirmed that an embryo grown in this new medium was no more likely to
implant in the uterus, many clinics switched back to their old media. But some clinics
continue to use and advertise EmbryoGlue, in spite of the evidence that it doesn't work.
Scott becomes frustrated when doctors ignore the scientific facts in order to meet
patients' demands.
"I think a lot of the problems we have in this industry is that it moves too fast,"
Scott says. "There is a very, very demanding consumer. The consumer is driving it. And
the consumer is a desperate person," who longs for a baby.
These patients beg their doctors for hope. When everything that is standard
procedure has failed, doctors start looking to the most recent developments for something
else to try. All it takes is one scientific paper for an idea to be noticed by the entire
industry. All it takes is one study saying that Medium A works better than Medium B for
every reproductive medicine clinic in the country to switch their brand of media.
The jury is still out for PGD. There is continued support for its use as a clinical
tool, but its disappointing success rates for infertile couples (given the fanfare) has caused
some doctors to conclude that the test doesn't greatly help patients, leading them to reject
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the technology altogether. For that matter, many medical professionals are unsure what
statistics to believe about PGD at all. The only statistics available are generated by the
laboratories that do PGD testing, and these facilities appear to face conflicts of interest.
The same doctors that pioneered the use of PGD in infertility also established profitable
businesses that promote it. They report that PGD increases an embryo's chance of
implantation by two-fold-from 10 to 20 percent-and in the same breath advertise their
service. Even if these entrepreneurs are able to keep their scientific and monetary
interests separate, the apparent conflict leaves a number of members of the community
concerned.
Another reason some people hesitate to support widespread access to PGD is that
it may open the floodgates for selection of embryos based on either sex-often called
family balancing-or such non-medical traits as intelligence or appearance. When PGD
is used to analyze chromosomes, the results include identification of the sex
chromosomes. The doctor then knows that embryos 1, 4, 5, and 7 will be girls and
embryos 2, 3, 6, and 8 will be boys. Most clinics, including FCNE, don't allow the
patient to choose the sex of the embryo to be transferred, but some facilities will.
It's impossible to know what percentage of PGD babies have had their sex
selected by their parents because clinics are not required to report the number and type of
cases they perform. In Europe, where infertility treatments are paid for by socialized
health care, restrictions on family balancing have become increasingly tighter. In the
United States, however, sex selection appears inevitable as long as infertility treatments
are market-driven. If a consumer wants to determine the sex of her baby, she can go to
the clinic that allows her to do so. If she is already paying for IVF and PGD for fertility
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reasons, there is no barrier, other than perhaps her own ethical stance, holding her back
from selecting her baby's gender. If the pro-PGD doctors get their way and every IVF
case is accompanied by PGD, more than 40,000 women will have their embryos tested.
The greater the number of people getting PGD the more room there is for niche markets,
such as family balancing. If every IVF patient does PGD, the total number of women
who both want to and can choose their baby's gender will increase.
But what if people who aren't infertile want to use PGD for family balancing?
What if it becomes possible to select embryos for non-medical traits? In Dr. Scott's
opinion, these ethical issues will not be faced on a significant scale, because the IVF
process is so difficult on a woman's body.
"You take these nasty shots twice a day. Every day," Scott says. "You come in for
blood sticks. You end up looking like a pincushion. You go through surgery. You have
your ovaries stuck. You've got vaginal probes in you every day. There's nothing private
about this. Everyone is in there all the time. Your husband is in and out giving sperm
samples to all sorts of people. He has to ejaculate in a little room into a little cup. There's
nothing romantic about this."
If someone wants to use PGD for superficial purposes, they are going to have to
go through the same painful and physiologically difficult procedure that an infertile
couple experiences.
"If you're that egotistical and you're that arrogant that you're going to design a
perfect little baby, you aren't going to be the person who's going to go through IVF and
PGDI," Scott says.
The people who go through IVF and PGD are like Devina and Barry.
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After eleven years, five states, five miscarriages, and two IVF cycles, Devina and
Barry are still not pregnant. Yet, they have hope.
Their journey with infertility began shortly after they were married, when Devina
was diagnosed with endometriosis and her doctor told her that if she wanted children, she
should try to get pregnant as soon as possible.
"Do it while you can," Devina recalls with a smile. "So basically we've been
trying for eleven years."
But while Devina and Barry became pregnant on their own approximately once
every two years, those pregnancies always ended in miscarriage. When they first started
seeking treatment they were living in Arizona, which doesn't require insurance
companies to cover IVF. They did the treatments they could afford, which included
intrauterine insemination and drugs that would stimulate ovulation. While waiting month
after month to see if Devina would become pregnant, the couple also began to slowly
save up the $9,000 to $17,000 it would cost to try a single cycle of IVF. That's one egg
retrieval, one batch of fertilizations, and one embryo transfer. Their journey continued in
the same vein from Washington to Iowa to Texas. Where no IVF insurance coverage is
mandated, none is provided. They continued to save.
When I:)evina and Barry moved to Massachusetts they were thrilled to discover
that the state requires insurance companies to cover IVF. Devina braved the shots, the
blood draws, the exams, and the surgery to finally try IVF. She got pregnant, and then
miscarried.
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Following her doctor's recommendation, they tried IVF again, but this time with
PGD. Before the embryos were transferred back into Devina, PGD was used to look for
chromosomal abnormalities in the biopsied cells.
Four embryos were produced from that round of IVF, and one cell from each was
sent to West Orange, New Jersey. The results came back. One had no genetic material at
all, but that might have been because it was lost in the biopsy process. The second had
only one X chromosome and no Y chromosome and would have led to miscarriage if it
had been transferred. The third would have also failed because it had two X
chromosomes and one Y chromosome. The last one was normal and had the sex
chromosomes of XY. They had one normal embryo.
"When they said our only normal embryol was XY, I looked at my husband and
said that means it's a boy. The smile that came over his face I will never forget," recalled
Devina. I'm sure that he would have had that same smile if it was a girl, but he just kept
repeating over and over for a couple of minutes 'so it's a boy, so it's a boy."'
When Devina became pregnant, the couple thought, "This is it." Finally they were
going to become parents.
"We felt very hopeful because the way that it was described was that if there was
a genetically normal embryo that there would only be a ten percent chance of
miscarriage," says Devina. In reality, according to Dr. Scott, patients like Devina have a
much higher chance of miscarriage then ten percent, even with PGD. This shows the
danger in giving patients a new technology into which they can invest all of their hope.
When patients are in such a precarious position, it's very easy for them to latch onto
wrong information.
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"I know in my mind that it's not a baby," Devina says. "I know this. But when
you see that embryo being transferred into your uterus, it's like, oh my god, there's my
child. I know that it's not logical, but it's just an over whelming feeling. Maybe it's just
the well of hope-it's just so full."
But, yet again, the pregnancy ended in miscarriage.
In reviewing her medical history, her doctors realized that a routine test had not
been done. There is a correlation between recurrent miscarriage and a blood-clotting
factor caused by a genetic trait called the Prothrombin gene mutation. A simple and
routine genetic test, which had been overlooked, was then conducted. Devina carried the
mutation. If she had been taking a drug called heparin, which prevents blood from over-
clotting before and during her pregnancy, she may not have miscarried. Barry was
furious. Devina was distraught.
They had tried everything, and nothing worked. But Devina and Barry believe
that PGD did work. Even though she miscarried, she became pregnant with the embryo
that was deemed genetically normal by PGD. This gives her hope that if they had known
about the blood-clotting factor she would have had a baby boy nine months later.
Devina knows that there is limited data showing that PGD really helps women get
pregnant. But, she also says that not everyone has the luxury of time to sit around and
wait for scientists to establish some kind of proof. Logically, PGD should help a woman
get pregnant, and Devina doesn't have time to waste. It's the needs of people like Devina
that reach for the latest technologies as a new source of hope.
Perhaps the most difficult thing for Barry and Devina is the waiting. They waited
nine years to be able to do IVF, and even now they are facing delays.
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"When you build up that strength to say okay, we're going to do another cycle
and then little things seem to get in the way, whether it's finances or you're required to
do one more test, it's very, very stressful, says Devina.
In the face of so much personal tragedy, Devina and Barry manage to stay
remarkably positive, with perhaps one exception.
"I think one of the things that we are mad about is that we have to choose between
building a family and having a home of our own," says Devina. "Even now, PGD isn't
covered by insurance, which is still $2000 that we are paying and then you have all of the
deductibles, which easily add up. Our first IVF here in Massachusetts wasn't covered
100% and we had to pay thousands of dollars."
The desire to become parents can support even the heaviest burden. Devina and
Barry have not lost hope.
Infertility affects 6.1 million people in the United States. One in six couples who
try to get pregnant will have problems. In recent years, infertility has been called an
epidemic and a national health crisis. But whether this problem is actually on the rise is
still in dispute.
Until recently, infertility was a hushed topic. The number of people before 1980
who found themselves unable to have a baby will probably never be known, as there were
few major medical or social efforts tracking infertility. In comparison to the American
Medical Association, which was founded in 1847, the 60-year-old American Society of
Reproductive Medicine is in its youth. Without a documented history, it is difficult to
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know whether the number of people facing infertility has been climbing or if it is just
being diagnosed more often.
One factor that could possibly contribute to an increase in couples seeking
infertility treatment is the older age at which women are deciding to have children. A
couple, with normal functioning reproductive systems, has a 25 percent chance of getting
pregnant in any given month. That same couple will have only a 10 percent chance each
month after the woman turns 35. Therefore, women who take time to establish careers
before settling down to start a family are more likely to face fertility problems.
For 80 percent of infertility cases, the cause can be determined. A third of the
diagnoses are attributed to the female, a third are attributed to the male, and a third are
related to both partners. For women, infertility can be caused by an obstructed fallopian
tube, low ovarian reserve, excess or very low body fat, or a hormonal imbalance. A man
may face infertility if he has a low sperm count, low sperm motility, or has been exposed
to harmful chemical or environmental conditions. For the diagnoses that are linked to
both partners, the problem is the result of compounding complications. For example, a
woman may have a slightly low ovarian reserve, meaning that her ovaries don't have
many eggs left, and her partner may have slightly low sperm motility. The combined
effect of each partner's reduced fertility keeps the couple from getting pregnant.
Even though diagnoses are split evenly between the sexes, it is women,
particularly women of advanced maternal age, who are most active in the infertility
community. Many of these women are intelligent, educated, and driven. Whether or not
the number of cases has reached the level of a national health crisis, many women are
determined to educate the public and remove the stigma of infertility.
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Thirty years ago, a time when women were gaining political and social power and
infertility was not spoken about openly, the national infertility association RESOLVE
was established. RESOLVE's primary goal is to bring infertility out of the closet so that
people can have access to accurate information about available treatment options. While
the organization only has 15,000 active members, there are typically more than a million
information requests made through RESOLVE's hotline and website. Much has changed
in thirty years.. Since its founding RESOLVE has fought for state legislation requiring
insurance companies to cover infertility treatments, and has won in fifteen states,
including Massachusetts. The 2003 Miss International's service platform was,
"Infertility: A National Health Crisis," radio stations play advertisements for fertility
clinics, and Lee Rubin Collins, a member of the national board for RESOLVE, can sit
and talk openly about her struggle with infertility in Starbucks.
Collins exemplifies the case of a successful woman who put her baby-making
years on hold. She graduated summa cum laude from Harvard University and received
her J.D. from Harvard Law School. She went on to work as a trial attorney and become a
partner at Ropes & Gray, one of Boston's oldest and largest law firms. When she turned
36, Collins had her first daughter. She wanted to have more children, but after six months
of trying to get pregnant again without results, she decided to see a specialist. Her doctors
discovered that due to an infection she developed while giving childbirth, one of her
fallopian tubes had closed. This cut her chances of getting pregnant in half. She was also
now 38-years-old, and a few years can make a huge difference in a woman's fertility.
Secondary infertility-when a woman can't get pregnant after she has already had
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children-appears to have become more common as women choose to start their families
later.
Collins proceeded with the normal series of treatments, first taking drugs to
stimulate egg production, then trying intrauterine insemination, and finally doing IVF. To
bring her second child into the world, she went through the IVF procedure five times.
Today Collins might have been offered PGD, but five years ago examining an embryo's
chromosomes wasn't done. After the birth of her second daughter, her family finally
complete, Collins became more active in the infertility community. She became a
member of the board for the local Massachusetts RESOLVE chapter, and a few months
later, was elected to the national board.
Collins never had to make a decision about whether or not to use PGD. However,
she has witnessed the ever-increasing clamor for the test among members of RESOLVE
who are currently seeking treatment. It is a new technology-a new hope.
"I have definitely encountered couples who have had failures with infertility
treatments who are really looking for answers, information, and any treatment that will
help them have that baby," says Collins. "PGD happens to be one of the newest
developments, so certainly it is of interest to people who are having difficulty with
infertility treatment."
She stresses, however, that PGD is not for everyone. Even if every IVF patient
were to do PGD as well, the total number of babies born would only make up one percent
of the births in the United States. Here is where RESOLVE gets caught in an awkward
position. Technologies such as IVF and PGD are controversial in themselves because
they involve the creation and destruction of embryos. Given people's ethical concerns,
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RESOLVE stresses that only five percent of couples who seek infertility treatment end up
using IVF. At the same time, RESOLVE advocates state-mandated insurance coverage
for infertility treatments because many people are unable to afford to pay for the more
expensive technologies. A delicate balance must be struck between saying that infertility
deserves more attention and stating that the controversial technologies that can help
patients aren't used widely enough to warrant ethical concerns.
Collins is acutely aware that negative reports about the use of PGD for purposes
other than infertility can have a harmful effect on the public's perception of the infertility
community. She was saddened when the Washington Post ran a front-page story about
how PGD can be used for sex selection. The article told the story of how a woman with
three daughters decided to use PGD to have a boy. She traveled from her home in
Massachusetts to a clinic in California, and while her daughters visited Disney Land,
artificially conceived twin boys. Collins worries that when the media or social scientists
call attention to these rare cases it makes the rest of the PGD world look bad.
"I think theorists spend so much time worrying about marginal cases that it's
ridiculous: What is it going to be like if we have a society where every person selects sex
of their embryo? I don't know but contact me in 500 years when it has a possibility of
being true," says Collins.
Deaf people have also used PGD to choose embryos that will grow into deaf
children, and dwarfed people have selected embryos in order to have children like
themselves. For someone like Collins, who is worried about the perception of advanced
reproductive technologies, the fact that these kinds of cases create headlines is very
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frustrating. These controversial goals are not shared by the majority of patients seeking
PGD. Most people are like Devina and Barry.
"We are every day women and men who want to have babies. We want to be
good parents. We want to help bring up the next generation of American children. We are
as American as apple pie," says Collins.
After her last, most devastating miscarriage, Devina joined RESOLVE. Offering
support in the form of informational meetings, personal testimonies, and online chats, she
fell in love with the organization and its sense of community. When an advertisement
was posted that the national helpline was looking for part time peer counselors, Devina
jumped on it. In less than a year she became director of the helpline service.
Devina is a PGD believer. She speaks about her work on the hot line with the
enthusiasm of an evangelical. When people who are struggling from infertility call, she
makes sure that they have information about PGD. To her, the technology just makes
sense. If a couple is going to put themselves through the difficult process of IVF, why not
spend a few thousand dollars more to make sure that the embryos being implanted are
normal? As a peer counselor, she tells callers about her personal experience. She explains
to people every day about how PGD helped select her only normal embryo, how she
became pregnant, how she miscarried due to an unrelated blood-clotting factor, and how
she has faith that next time she will be taking a baby home in her arms.
But Devina's faith is based on a personal experience and not on studies published
in scientific journals. When tells people about PGD on the hotline, she speaks from her
heart. There is a grave risk of passing on misinformation.
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A five-minute drive from Manhattan, just on the other side of the Lincoln Tunnel,
lives Dr. Santiago Munn, his wife, and his six-month-old daughter. While being a
laboratory director rarely denotes celebrity status, to people like Devina, Munn is
practically a rock-star. He signed off on the chromosome results from her last PGD test,
and he will likely autograph the next as well.
Munne is the director of Reprogenetics in New Jersey. Fertility clinics all over the
world, including FCNE, send slides with fixed cells to be examined by Munn's staff.
Since its founding in 2000, the company has become the largest PGD laboratory in the
world. More that 1,500 cases were completed last year, and 85 percent were for infertility
patients.
His lab labels chromosomes numbered 13, 15, 16, 17, 18, 21, 22, and the sex
chromosomes with fluorescent probes. Looking under a microscope, a technician checks
each cell to see if it received one copy of each chromosome from mom and one from dad.
We receive 23 chromosomes from each of our parents, but the current technology limits
the total number of chromosomes that can be more closely examined to eight. These
specific chromosomes were chosen for PGD testing because they are often found to be
abnormal in miscarried fetuses. The total bill paid to Reprogenetics is $2,200.
Munn6 shrugs when asked about the price of PGD. "It's expensive in what you
compare it to," he says.
In places like Massachusetts, where IVF is covered by insurance, patients are
often surprised and upset when they are informed that PGD is not covered and they must
pay out of pocket for the testing. But for patients that are already financing $14,000 to
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cover the cost of IVF, the additional $2,200 doesn't seem like much of an additional cost.
In fact, if doing PGD means that a couple is more likely to get pregnant and less likely to
have to pay another $14,000 for a second IVF treatment, the cost of PGD pays for itself.
Examining the currently available statistics does little to clear up the issue of
whether PGD is worth the price. This is because the scientific papers that report success
rates of PGD are produced by individual clinics, which work with small and isolated
groups of patients. Many doctors, including Munn6, are calling for a national effort to
gather information about PGD and the clinics that offer it. This kind of data collection
and clinic monitoring is already in place for IVF. The CDC keeps a registry that includes
information about most fertility clinics in the country, including the number of patients
seen per year, the kinds of procedures performed, and clinics' success rates. It's a
voluntary registry, but fertility clinics that do not submit their statistics are listed as not
participating. Based on the gathered data, the CDC reported that the chance of a woman
having a baby after one IVF procedure was 33.4 percent.
Citing a paper that was published in 1999 by one of his colleagues, Munn6 claims
that PGD doubles the chance that an embryo will implant in the uterus. The study
reported that the chance of implantation for a woman in the control group was 10.2
percent. The PGD patients on the other hand, had a 20.5 percent chance of getting
pregnant. Munn6 himself published a similar paper in 2003 that looked at slightly older
patients. Again he reported a two-fold increase, this time from a 10 percent to 20 percent
chance of implantation. In both studies, the control groups and PGD patients groups had a
lower than average chance of getting pregnant. This inconsistency could exist because the
people who seek out labs like Munn6's are the toughest cases. It could also be because
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Munn6 advises transferring no more than three embryos back into the patient's uterus. He
does this in order to reduce the likelihood of twins or triplets, which are high-risk
pregnancies, but it may reduce the overall success rate. Whatever the cause, the
discrepancy casts some doubt on the effectiveness of PGD for infertility.
While 85 percent of the embryos that Reprogenetics tests are from patients
struggling with infertility, a small subset of these patients are definitely being helped by
PGD. Ten percent of the patients that the lab tests have infertility caused by
translocations. These special kinds of abnormalities are not caused by a woman's aging
eggs but by a genetic problem in one partner's own chromosomes. A person with a
translocation has a piece of one chromosome switched with another chromosome. For
example, a piece of chromosome number one could be attached to number three and a
piece of number three hooked onto number one. A translocation is "balanced" when the
same amount of genetic material is swapped between chromosomes. While people with
balanced translocations appear completely normal, many eventually find themselves
facing infertility.
When a cell with a balanced translocation divides up its genetic material to make
eggs or sperm, the chromosomes can break. These broken chromosomes often generate a
translocation that is "unbalanced," where the exchange of material between chromosomes
is uneven. An unbalanced translocation typically prevents an embryo from implanting in
the uterus or results in miscarriage the same way that an embryo with a chromosomal
abnormality does.
For patients struggling with this specific kind of infertility, PGD is very useful.
Selecting the embryos that do not have a translocation improves the chances of getting
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pregnant dramatically. The same type of cell biopsy, cell fixation, and fluorescent
probing techniques are used to distinguish the normal embryos from the abnormal ones.
Reprogenetics charges $2,500 for its portion of the testing.
As Munn6 sits back comfortably into his couch and talks about PGD, he radiates
confidence. He explains, again, the logic of PGD: it just makes sense to check the
embryos' chromosomes before transferring them back to the patient. He admits, however,
that the success rates are not as high as the scientific community had hoped. The reasons
he gives as to why more people are not benefiting from PGD are almost entirely based on
things beyond his control. His step in the procedure is to look that the cells already fixed
to the slides. The first problem he cites is that success rates vary depending on who is
performing the PGD.
"There is a learning curve with these technologies," Munn6 says.
PGD is a delicate procedure and expertise is needed to produce consistent results.
Though Reprogentics was only established in 2000, its team of scientists has been
involved in the field for over a decade. Munn6 himself wrote a seminal paper in 1993 that
first suggested that PGD could be used to treat infertility patients. While experience is not
an issue for Reprogentics, Munn6 worries that other labs are offering PGD testing
without proper training and so are lowering overall success rates.
In order to protect patients from laboratories new to PGD testing, New York State
requires a specific laboratory license for the testing.
"For us Ithe lawI is great," Munn6 laughs. His facility is currently the only lab
with certification and therefore all of New York's business is sent to Reprogentics. But
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more importantly, he says, is that these kinds of laws help protect both the patients and
the reputation of experienced PGD laboratories from the unqualified facilities.
"There are some groups that shouldn't be doing PGD. People will say it's not
working because in their hands it's not working," Munn6 says.
Another reason Munn6 gives for the lower success rates is that "damage must be
compensated by the selection." The cell biopsy procedure causes some trauma to an
embryo and there is a higher percent chance that a biopsied embryo will stop growing
and never grow into a baby. Therefore, PGD's selection process must be more helpful
than the cell biopsy procedure is harmful. But this is not always the case.
For example, a couple might produce five embryos but only one is pretty. PGD is
done, and the test shows that the only normal embryo is the pretty one. So this embryo,
which would have been selected without PGD, has been traumatized by the cell biopsy
procedure and is now less likely to result in a pregnancy. This kind of case actually pulls
down PGD's success rate, and is the reason that Munn6 recommends doing PGD only for
patients who have produced at least six embryos. However, if a doctor sends him a slide
with cells from less than six cells fixed to it, he does not turn down the case.
Munn6 suggests that the take-home-baby rate could increase dramatically if more
research were clone to improve the cell biopsy process. But his laboratory doesn't do that
part of the test. Like the advancement of the cell biopsy technique, Munn6 leaves the
pondering of ethical questions to others.
Despite some public worry about the potential abuse of PGD, Dr. Munn6 has no
reservations about the technology at all. He believes that the desire to practice better
medicine will require PGD to be done with almost all IVF, and that will be a good thing.
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Even when confronted by the controversial topic of family balancing Munn6 does not see
a problem. In the U.S. couples request girls as often as they do boys, he says.
Regardless of his personal feeling, the New York State regulations provide
Reprogenetics with an easy way out of a sex selection controversy. The law requires that
all information deemed from testing results be passed on to referring physician. This
includes the sex of each embryo.
"How this information is used, 1 don't know," says Munne.
If Munn6 is the name and face that infertility patients recognize, Mark Hughes is
the hero to people like Kevin DeLegge, Alison Finn, and Lynette Scott. They refer to him
as "the saint." Like Munn6, Hughes is the director of a PGD laboratory, but unlike
Munn6, he doesn't run tests for infertility patients and he doesn't have a luxury apartment
minutes from downtown Manhattan. The Genesis Genetics Institute makes up no more
than a thousand square feet of the Samaritan Hospital in downtown Detroit, and there is
nothing lavish about it.
Hughes calls himself a geneticist and a scientist. He is neither an entrepreneur,
nor a reproductive medicine physician, though he has started his own laboratory and has
a medical degree. It was because he was a geneticist that he entered the burgeoning world
of PGD back in 1989.
In that year, a team of researchers at Hammersmith Hospital in London reported
the first PGD pregnancy. In order to avoid a disease that would be inherited only by sons,
female embryos were selected and transferred back into the patient. The results were
reported in Nature, and the story rocked the reproductive medicine community. The team
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tried the procedure again, but this time had a misdiagnosis and a male embryo was
mistakenly transferred.
"And then they realized that they were embryologists and reproductive doctors.
They weren't molecular biologists and geneticists," says Hughes. "If they were going to
make this work, they had to bring together these different groups with different
experiences."
So they called Hughes, and he joined the research team. They did the next twelve
PGD cases together, all of which were for screening out embryos that would have
become children with cystic fibrosis. This was the beginning of PGD-grounded in
collaborative science and intense research. Hughes recalls with genuine nostalgia the time
before egos were at stake and financial interests were in play.
One of his happy memories includes sitting around at the hospital with his
colleagues, waiting for an experiment to finish up, and trying to come up with a name for
their procedure.
"We had a list: blastomere, embryo, reproduction, genetic, in vitro," says Hughes.
"Then we thought, 'preimplantation diagnosis.' But that would be PID, which in the
medical community stands for 'Pelvic Inflammatory Disease' which wouldn't be good.
So we came up with the term BABI : blastomere analysis before implantation. That was
the term. But it never took off. PGD became the term."
Today, Hughes does similar work with PGD as he did more than thirteen years
ago. He tests embryos for specific genetic diseases that the parents carry. He believes that
this is where PGD can help people the most: making sure that a baby is born without a
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genetic disease. It is a process that is more difficult and requires more precision than
chromosome testing for infertility patients.
The testing procedure at Reprogenetics resembles an assembly line. First, the
slides with cell nuclei fixed and clearly labeled are received. Next the technicians add the
fluorescent markers, examine the chromosomes, and the results are then sent back to the
patient's fertility clinic. The testing that goes on at Mark Hughes' lab, on the other hand,
is custom in nature. He first spends an hour on the phone consulting with each patient.
Next he receives the couples' blood and confirms the family's mutation. The testing is
then fine-tuned for the specific mutation. Finally, the biopsied cells are tested and the
results reported back to the patient's physician. More than a thousand cases per year are
sent to Mark Hughes' lab.
"We do all of that for $2,500," says Hughes. "That's why we're basic. That's why
we don't have anything on the walls. We're not trying to be glitzy. We're not trying to
impress people. We're just trying to do good science."
No one speculates whether Mark Hughes runs a PGD lab to make money. If
anything, people wonder how he manages to stay open. The persistent hum of the
sequencing machine and the large stack of patient files on his desk are signs that even if
good science hasn't made him rich, it sure has kept him busy.
It's not that Hughes doesn't want to see PGD used to treat infertility patients.
Rather, he just doesn't believe that the science is strong enough to warrant all of the hype.
"I'm not convinced that it helps most patients," says Hughes. "A few years ago,
we all stood up at genetics meetings and reproductive meetings and we said, 'now this is
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going to be the best thing since sliced bread!' But the bottom line is that it isn't
improving the take-home baby rate at all."
This, however, is not what Devina and Barry were told, and it's not what they
believe. They have put their lives on hold to pursue the dream of having a baby and pin
their hope on prayers and PGD. But Hughes, a respected scientist and neutral party-who
has nothing to gain or lose by the success of an infertility treatment-doesn't see
evidence for the procedure in which the couple entrust so much hope.
"Geneticists, we tend to be pretty cautious folks," says Hughes. "The reproductive
people tend to be exactly the opposite. They adopt every new technology that comes
along, because if they don't, the people down the street will advertise it as being an
important add-on, or adjunct test to help you."
It may be too easy to fault the people collecting the checks for the acceptance of
misinformation, because the patients themselves are partially to blame. The desire for
hope is a powerful part of the human condition, and people suffering from infertility find
hope in both prayers and science. What doctors offer are not just tests, pills, and
surgeries. Their potential treatments are the very embodiment of hope.
Yet when the coldness of scientific accuracy collides with the burning desire for a
family the result is either relief or more heartache. A small fraction of couples assuredly
come away pleased. They successfully complete their family. Other couples find relief in
simply concluding treatment. After years of moving from one procedure to the next,
being physically, financially, and emotionally beaten, the journey ends. Currently, PGD
marks the end of infertility treatment. It means they have tried everything, which makes
the most comforting technology a couple can buy. But there are those whose desire to
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achieve parenthood are all consuming. They never rest, and continue to wait for the next
new thing.
After having spent thousands of dollars and years of their lives trying to have a
baby, Devina and Barry are not done yet. Devina will take medication for her blood
clotting factor and try PGD again. She is unsure what options she will pursue if she fails
to get pregnant. But right now, all that matters is that there is another month of treatment
in which to find hope.
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